53708-55-7

Usage

Uses

Used in Pharmaceutical Research:
(2S)-3-(1H-indol-3-yl)-N~1~-methylpropane-1,2-diamine is used as a research compound for exploring its potential physiological effects and therapeutic applications. Its presence in the class of tryptamine alkaloids suggests it may have roles in neurotransmission and could be instrumental in the development of new drugs targeting the nervous system.
Used in Biochemical Studies:
In the field of biochemistry, (2S)-3-(1H-indol-3-yl)-N~1~-methylpropane-1,2-diamine serves as a subject for understanding the interactions between molecules and their biological targets. Its structure and activity can provide insights into the mechanisms of various biochemical processes.
Used in Psychotropic Drug Development:
Given its potential psychoactive effects, (2S)-3-(1H-indol-3-yl)-N~1~-methylpropane-1,2-diamine is used as a starting point for the development of psychotropic drugs. Its effects on neurotransmitters may lead to the creation of novel treatments for mental health disorders.
Note: The specific applications mentioned are hypothetical and based on the general properties of tryptamine alkaloids. The actual uses would depend on the outcomes of further research and development.

Upstream product

• 5241-64-5 BOC-tryptophane 
• 53708-63-7 tryptophan methyl amide 

Relevant academic research and scientific papers

3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists

Early structure-activity studies on racemic tryptophan ester and amide NK- 1 antagonists 5-7 led to the discovery that the potency of the series could be markedly increased by moving the carbonyl function in these molecules to an off-chain position as in the 3-aryl-1,2-diacetamidopropane 9. Further medicinal chemistry incorporating this change resulted in the discovery of a novel series of highly potent aryl amino acid derived NK-1 antagonists of the R stereoisomeric series (IC50's = 100 pM to >5 μM). Compounds in this series were shown to be competitive antagonists using an in vitro NK-1 smooth muscle assay, and this data correlated well with observed human NK-1 binding affinities. Two of these agents, (R)-25 and (R)-32, blocked intrathecal NK-1 agonist-driven [Ac-[Arg6, Sar9, Met(O2)11]-substance P 6-11 (Ac-Sar9)] nociceptive behavior in mice. Both compounds potently blocked the neurogenic dural inflammation following trigeminal ganglion stimulation in the guinea pig after intravenous administration. Further, upon oral administration in this model, (R)-32 was observed to be very potent (ID50 = 91 ng/kg) and have a long duration of action (>8 h at 1 μg/kg). Compound (R)-32, designated LY303870, is currently under clinical development as an NK-1 antagonist with a long duration of action.